PMID- 29724989 OWN - NLM STAT- MEDLINE DCOM- 20180928 LR - 20210617 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 24 DP - 2018 May 4 TI - Role of Hypoxia-Inducible Factors 1alpha (HIF1alpha) in SH-SY5Y Cell Autophagy Induced by Oxygen-Glucose Deprivation. PG - 2758-2766 LID - 10.12659/MSM.905140 [doi] AB - BACKGROUND HIF-1alpha plays an important role in hypoxia-ischemia brain damage. Accumulating evidences demonstrates that HIF-1alpha can contribute to cell autophagy. Oxygen-glucose deprivation (OGD) is a commonly used ischemic model in vitro. Our study was performed to investigate the influences of HIF-1alpha on autophagy in SH-SY5Y cells under OGD treatment. MATERIAL AND METHODS An OGD model was constructed in SH-SY5Y cells. PI method and MTT assay were used to test cell death and viability, respectively. Western blot assay was used to estimate the protein levels of HIF-1alpha and LC3. Quantitative GFP-LC3 light microscopy autophagy assay was performed for SH-SY5Y cells. 2ME2 and siRNA-HIF-1alpha were applied to investigate the effects of HIF-1alpha-knockdown on LC3 expression. Additionally, 3-MA (autophagy inhibitor) and autophagy inducer rapamycin (Rapa) were used to investigate the effects of autophagy on cell survival under OGD condition. RESULTS Under OGD, the apoptosis of SH-SY5Ycells was increased while cell viability rate was decreased. The expression of HIF-1alpha was increased along with the advancement of OGD treatment and achieved the highest level at 24 h. However, inhibiting HIF-1alpha expression decreased the cell apoptosis and increased cell viability. LC3-II expression was gradually increased with the duration of OGD condition and knockdown of HIF-1alpha resulted in decreased expression of LC3. Inhibiting autophagy significantly enhanced the viability and reduced the apoptosis of SH-SY5Y cells, while enhancing autophagy showed the opposite effects. CONCLUSIONS Enhanced expression of HIF-1alpha may be related to autophagy activation in SH-SY5Y cells, thus contributing to ischemic/hypoxic brain damage. FAU - Niu, Guohui AU - Niu G AD - Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). FAU - Zhu, Dengna AU - Zhu D AD - Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). FAU - Zhang, Xiaoli AU - Zhang X AD - Department of Pediatric Internal Medicine, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). FAU - Wang, Jun AU - Wang J AD - Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). FAU - Zhao, Yunxia AU - Zhao Y AD - Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). FAU - Wang, Xin AU - Wang X AD - Department of Pediatric Rehabilitation, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland). LA - eng PT - Journal Article DEP - 20180504 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (MAP1LC3A protein, human) RN - 0 (Microtubule-Associated Proteins) RN - 0 (RNA, Small Interfering) RN - 147336-22-9 (Green Fluorescent Proteins) RN - 5142-23-4 (3-methyladenine) RN - IY9XDZ35W2 (Glucose) RN - JAC85A2161 (Adenine) RN - S88TT14065 (Oxygen) RN - W36ZG6FT64 (Sirolimus) SB - IM MH - Adenine/analogs & derivatives/pharmacology MH - Apoptosis/drug effects MH - *Autophagy/drug effects MH - Cell Hypoxia/drug effects MH - Cell Line, Tumor MH - Cell Survival/drug effects MH - Gene Knockdown Techniques MH - Glucose/*deficiency MH - Green Fluorescent Proteins/metabolism MH - Humans MH - Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism MH - Microtubule-Associated Proteins/metabolism MH - Models, Biological MH - Oxygen/*metabolism MH - RNA, Small Interfering/metabolism MH - Sirolimus/pharmacology PMC - PMC5954843 EDAT- 2018/05/05 06:00 MHDA- 2018/10/03 06:00 PMCR- 2018/05/04 CRDT- 2018/05/05 06:00 PHST- 2018/05/05 06:00 [entrez] PHST- 2018/05/05 06:00 [pubmed] PHST- 2018/10/03 06:00 [medline] PHST- 2018/05/04 00:00 [pmc-release] AID - 905140 [pii] AID - 10.12659/MSM.905140 [doi] PST - epublish SO - Med Sci Monit. 2018 May 4;24:2758-2766. doi: 10.12659/MSM.905140.